A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/20/2019
Start Date:May 31, 2013
End Date:June 30, 2019
Contact:Eisai Medical Information
Email:esi_oncmedinfo@eisai.com
Phone:1-888-274-2378

Use our guide to learn which trials are right for you!

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity
ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in
dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777
that is being used to test efficacy and safety.

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent
or persistent Cutaneous T-Cell Lymphoma (CTCL). The study consists of an initial Lead-in part
(to select recommended dose of E7777 for Main part), followed by the Main part (to test
efficacy). Lead in part is complete and main study is ongoing. Participants will move through
three phases while on study: Pretreatment Phase, Treatment Phase, and Extension Phase and a
Follow-up Period.

Inclusion Criteria:

Participants must meet all of the following criteria to be included in the study:

1. Age greater than or equal to 18 years.

2. Histopathologic diagnosis of CTCL (mycosis fungoides [MF] or Sezary Syndrome [SS]),
confirmed by skin biopsy, or lymph node, or blood assessment, of current disease.

3. CD25 assay-positive tumor, defined as detectable CD25 on greater than or equal to 20%
of total lymphoid infiltrate in biopsied lesions by immunohistochemistry.

4. CTCL disease stage at study entry as follows, according to ISCL/EORTC (Olsen 2011).

- Lead-In Part: Stage IA - IV, except participants with CNS involvement.

- Main Study: Stage IA - IVA2 including lymph node disease N2 and N3

5. History of prior therapies for CTCL as follows: must have had prior therapy, any
number of prior therapies allowed.

Topical treatments (except topical chemotherapy) and steroids are not considered as
prior therapies.

6. A minimum washout period of 4 weeks after previous CTCL therapy is recommended before
the first dose of E7777.

Participants must have recovered from any adverse effects from any previous CTCL
therapy to Common Terminology Criteria for Adverse Events (CTCAE) Grade <2 before
starting study drug. A shorter washout may be allowed if participant is experiencing
progressive disease despite ongoing treatment.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 in the Lead-In
Part and performance status of 0 or 1 in the Main Study.

8. Life expectancy greater than or equal to 3 months in the Lead-In Part and greater than
or equal to 12 months in the Main Study.

9. Adequate bone marrow reserves as evidenced by:

- platelets greater than or equal to 100,000/mm3 (100 x 10^9/L)

- clinically stable hemoglobin greater than or equal to 9 g/dL (90 g/L) and
hematocrit greater than or equal to 27% without transfusion support

10. Normal hepatic function as evidenced by:

- bilirubin and alkaline phosphatase less than or equal to 1 x the upper limit of
normal (ULN).

- aspartate aminotransferase (AST) less than or equal to 75 U/L and alanine
aminotransferase (ALT) less than or equal to 100 U/L.

- albumin greater than or equal to 3.0 g/dL (30 g/L).

11. Adequate renal function as evidenced by serum creatinine less than or equal to 1.8
mg/dL (158 umol/L) OR calculated creatinine clearance greater than or equal to 50
mL/min (per the Cockcroft-Gault formula) with less than 2+ protein OR 24- hour urine
creatinine clearance greater than or equal to 50 mL/minute with 24- hour urine protein
less than 1g.

12. Provide written informed consent prior to any study-specific screening procedures.

13. Females may not be lactating or pregnant at Screening or Baseline

14. All females will be considered to be of childbearing potential unless they are
postmenopausal or have been sterilized surgically

15. Male participants must have had a successful vasectomy (confirmed azoospermia) or they
and their female partner must meet the criteria above

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:

1. Prior denileukin diftitox therapy

2. Use of topical steroids within 14 days of Day 1 of initial therapy is not
allowed.Topical steroids or systemic low dose steroids of less than or equal to 10
milligram per day (mg/day) prednisone are allowed in participants with erythroderma
who have been on corticosteroids for a prolonged period of time and where
discontinuation may lead to rebound flare in disease. The concomitant steroid
medication is allowed as long as the type of steroid, route of administration, and
steroid dose remain the same as what the participant had been receiving for a
prolonged period of time.

3. Active malignancy (except for CTCL, definitively treated basal or squamous cell
carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months.

4. Serious intercurrent illness

5. Significant cardiac disease requiring ongoing treatment, including congestive heart
failure (CHF), severe coronary artery disease (CAD), cardiomyopathy, uncontrolled
cardiac arrhythmia, unstable angina pectoris, or myocardial infarction (MI)

6. Significant pulmonary symptoms or disease

7. History of uncontrolled seizure disorder or active central nervous system disease

8. Major surgery within 2 weeks of study enrollment

9. Significant or uncontrolled infections requiring systemic anti-infective therapy

10. Known human immunodeficiency virus (HIV) infection; known active hepatitis B or
hepatitis C infection

11. Females who are pregnant (positive urine test) or breastfeeding

12. Any history of a medical condition or a concomitant medical condition that, in the
opinion of the investigator, would compromise the participant's ability to safely
complete the study.
We found this trial at
19
sites
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
500 22nd Street South
Birmingham, Alabama 35233
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
251 E Huron St
Chicago, Illinois 60611
(312) 926-2000
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Westmead, New South Wales 2145
?
mi
from
Westmead,
Click here to add this to my saved trials